YSYujia Shi

Yujia Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yujia Shi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Qian Zhang

    Department of Respiratory and Critical Care Medicine, the Second People’s Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China

    4 shared publications
  • Xinru Xiao

    Department of Respiratory and Critical Care Medicine The Second People's Hospital of Changzhou The Third Affiliated Hospital of Nanjing Medical University Changzhou China

    2 shared publications
  • Zhengdao Mao

    Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou, China

    2 shared publications
  • Chuang Mm Sun

    Department of Respiratory and Critical Care Medicine, the Second People’s Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China

    1 shared publication
  • Chuang Sun

    Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou, China

    1 shared publication
  • Chuang Sun

    Department of Respiratory and Critical Care Medicine, the Affiliated Changzhou NO.2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.

    1 shared publication

Latest Publications

  • Open Access

    Association between Streptococcus and chronic obstructive pulmonary disease: A two-sample Mendelian randomization study

    by Ziqi Mm Ding, Xinru Mm Xiao, Na Mm Li, Chuang Mm Sun, Yujia Shi

    Streptococcus is one of the most common causative agents of acute exacerbations of chronic obstructive pulmonary disease (COPD). It may cause infection and inflammation in the lungs, leading to dyspnea and other symptoms. However, the causal connection between Streptococcus and COPD has not been elucidated. This study aimed to investigate the causal relationship between Streptococcus and the risk of COPD. Using a large-scale genome-wide association study database, a series of quality control steps were taken to select qualified single nucleotide polymorphisms that were strongly associated with exposure. Two-sample Mendelian randomization (MR) was used to evaluate the causal effect of Streptococcus on COPD, including inverse variance weighting, MR-Egger, weighted median, weighted mode, and simple mode. MR-Egger intercept tests, Cochran Q test, MR-PRESSO global test, and “leave-one-out” sensitivity analyzes were applied to assess horizontal pleiotropy, heterogeneity, and stability. Based on extensive genetic data obtained from genome-wide association studies involving 468,475 European participants, we included a total of 14 single nucleotide polymorphisms as instrumental variables. MR results confirmed an association between Streptococcus and a higher risk of COPD (odds ratio = 1.18, confidence interval = 1.01–1.38, P = 4.28 × 10-2). Analyses of heterogeneity (P > .05) and pleiotropy (P > .05) analysis confirmed the reliability of MR results. We verified the possibility of a causal link between Streptococcus and COPD, thereby highlighting the connection of the gut–lung axis.


  • Open Access

    MiR-4454 in Combined Allergic Rhinitis and Asthma Syndrome (CARAS): Clinical significance and mechanistic insights into airway inflammation

    by Zhiguang Liu, Chuang Sun, Yujia Shi, Zhipeng Wang, Lianzheng Zhou, Qian Zhang, Zhengdao Mao

    Abnormal expression of non-coding microRNA is associated with the development of combined allergic rhinitis and asthma syndrome (CARAS). However, the function of miR-4454 in CARAS is unknown. Our study aimed to reveal the clinical significance and related mechanism of miR-4454 in CARAS. Blood samples from 38 cases of CARAS and 43 cases of healthy subjects were collected to detect the expression of miR-4454. House dust mite (HDM) sensitization and challenge-induced bronchial epithelial cells to simulate the asthma state model in vitro, miR-4454 mimics and inhibitor transfection to detect the expression level of pro-inflammatory cytokines, cell survival rate and migration ability, flow cytometry and western blot (WB) Detection of cell cycle, apoptosis and inflammation-related protein levels. Compared with healthy controls, the expression of miR-4454 in the blood of CARAS patients was significantly up-regulated, and IL-6 and IL-8 were significantly up-regulated in the HDM treatment group, indicating that the model induction was successful. After overexpression of miR-4454, cell proliferation and migration in the HDM-treated group were significantly inhibited, and the levels of early apoptosis and inflammation-related proteins (IL-17, IL-17RD, TNF-α, GCSF and NF-κB) were increased High; after inhibiting miR-4454, cell proliferation and migration were significantly enhanced, and the levels of apoptosis and inflammation-related proteins were decreased. This study found that inhibiting the expression of miR-4454 can improve HDM-induced cell injury, which may be related to miR-4454 regulating the activation of IL-17/NF-кB inflammatory axis.


  • Open Access

    Application of metagenomic next-generation sequencing (mNGS) in diagnosing pneumonia of adults

    by Zhiguang Liu, Chuang Sun, Xinru Xiao, Lianzheng Zhou, Yanhua Huang, Yujia Shi, Xiaowei Yin, Zhengdao Mao, Qian Zhang

    Introduction: Accurate identification of pathogens that cause pulmonary infections is essential for effective treatment and hastening recovery in adults diagnosed with pneumonia. At present, despite metagenomic next-generation sequencing (mNGS) technology has been widely used in clinical practice for pathogen identification, the clinical significance and necessity of detecting pathogen in bronchoalveolar lavage fluid (BALF) for pneumonia-stricken adults remain ambiguous. Methodology: In this study, 80 patients suffering from pulmonary infection were enrolled, who were admitted to the Affiliated Changzhou Second People’s Hospital of Nanjing Medical University between January 2020 and September 2022. The diagnostic performances of mNGS and conventional methods (CM) were systematically analyzed based on BALF samples, and we further investigated the influence of mNGS and CM in diagnosis modification and treatment. Results: We found a significantly higher positive rate for the mNGS method in contrast to CM. Bacteria were the most common pathogens, and Streptococcus pneumoniae was the most commonly identified pathogen. Candida albicans and Epstein-Barr virus were the most frequently identified fungus and virus. Atypical pathogens such as Mycobacterium tuberculosis, virus Nontuberculous mycobacteria, and Chlamydia psittaci were also identified. A total of 77 patients were identified with mixed infections by mNGS. As the disease progressed and recurrent antibiotic treatment persisted, significant dynamic changes in the clinical manifestation from the BALF samples could be found by mNGS. Conclusions: This study underscores the efficacy of mNGS in detecting pathogens in BALF samples from patients suffering pulmonary infections. Compared with the CM, mNGS significantly enhanced the positive diagnosis ratio, particularly in diagnosing Mycobacterium tuberculosis, atypical pathogens, and viral or fungal infections.


  • Open Access

    A2M Serves as Promising Biomarker for Chronic Obstructive Pulmonary Disease

    by Xinru Xiao, Wei Cai, Ziqi Ding, Yujia Shi, Liang Fan, Qian Zhang

    Background: Chronic obstructive pulmonary disease (COPD) often associated with cigarette smoking. However, increasing evidence suggests that non-smoking COPD is much higher than previously thought. This study aims to identify a nonsmoking COPD biomarker and examined its value in diagnosis and prediction of acute exacerbation. Methods: A total of 35 stable COPD patients, 70 acute exacerbation chronic obstructive pulmonary disease (AECOPD) patients and 35 healthy control subjects were included. Plasma α 2 macroglobulin (A2M) and matrix metalloproteinase-9 (MMP-9) levels were measured using the enzyme-linked immunosorbent assay (ELISA) method on all participants. Their association with clinical characteristics and lung function parameters were determined by regression analysis. Receiver operating characteristic (ROC) curve was used to determine the diagnostic sensitivity and specificity. Correlation coefficients were evaluated using Pearson’s correlation. Results: Plasma A2M concentration was decreased and MMP-9 concentration, MMP-9/A2M ratio were elevated in stable COPD patients compared with control groups. And MMP-9 expression was significantly higher in AECOPD patients. A2M level was increased in AECOPD patients with infection compared with those without. In addition, there was no statistical difference in A2M levels between smokers and nonsmokers COPD or healthy control subjects. Furthermore, A2M, MMP-9 and MMP-9/A2M were correlated with forced expiratory volume in one second (FEV1)%, FEV1/ forced vital capacity (FVC), CAT and mMRC score in COPD patients, but had no correlation with fraction of exhaled nitric oxide (FeNO) and concentration of alveolar nitric oxide (CaNO). Conclusion: A2M is altered in peripheral blood of COPD patients and correlated with severity and infection. Moreover, there was no significant correlation between the change in A2M and smoking, FeNO and CaNO, suggesting A2M may reflect the overall rather than local inflammation in COPD patients and serve as a potential biomarker for nonsmoking COPD patients.


  • Open Access

    Overexpression of miR-155-5p Inhibits the Proliferation and Migration of IL-13-Induced Human Bronchial Smooth Muscle Cells by Suppressing TGF-β-Activated Kinase 1/MAP3K7-Binding Protein 2

    by Yujia Shi, Xingli Fu, Qi Cao, Zhengdao Mao, Yi Chen, Yun Sun, Zhiguang Liu, Qian Zhang

    Shi Y, et al. Allergy Asthma Immunol Res. 2018 May;10(3):260-267. https://doi.org/10.4168/aair.2018.10.3.260